Loading
Vemurafenib, the first drug targeting the BRAF V600E mutation, reduced deaths by 63 percent compared with dacarbazine chemotherapy in metastatic melanoma, launching targeted therapy in the disease.
Phase 3 trial of 675 patients with previously untreated BRAF V600E-mutant metastatic melanoma randomised to vemurafenib or dacarbazine.
At interim analysis, the hazard ratio for death was 0.37 and for progression 0.26, with response of 48 versus 5 percent; cutaneous squamous cell carcinomas, arthralgia and photosensitivity were the characteristic toxicities, and the data monitoring board recommended crossover.
BRAF testing became mandatory in advanced melanoma and vemurafenib the first approved BRAF inhibitor; combination with MEK inhibitors soon replaced monotherapy.
Shares Test intermittent dosing of targeted drugs to delay resistance, with honest priors, New England Journal of Medicine.
Shares Test intermittent dosing of targeted drugs to delay resistance, with honest priors, New England Journal of Medicine.
Shares Vemurafenib, BRAF V600-mutant melanoma.
Shares Test intermittent dosing of targeted drugs to delay resistance, with honest priors, Vemurafenib, BRAF V600-mutant melanoma.
Shares Test intermittent dosing of targeted drugs to delay resistance, with honest priors, Vemurafenib, BRAF V600-mutant melanoma.
Shares BRAF V600-mutant melanoma, New England Journal of Medicine.
Shares Vemurafenib, BRAF V600-mutant melanoma.
Shares Vemurafenib, BRAF V600-mutant melanoma.